Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
ABBV | NYSE | USD | Real-time | |
0QCV | London | EUR | Real-time | |
ABBV | BIVA | MXN | Delayed | |
ABBV | Mexico | MXN | Delayed | |
1ABBV | Milan | EUR | Real-time | |
4AB | TradeGate | EUR | Delayed | |
4AB | Frankfurt | EUR | Delayed | |
ABBV34 | B3 | BRL | Delayed | |
ABBV | Vienna | EUR | Real-time | |
ABBV | Lima | USD | Delayed |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Sell | Sell | Sell | Neutral | Buy |
Technical Indicators | Strong Sell | Strong Sell | Strong Buy | BUY | Strong Buy |
Summary | Strong Sell | Strong Sell | Neutral | Neutral | Strong Buy |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Emerging Patterns | |||||
Three Outside Down | 1H | Current | |||
Belt Hold Bearish | 1D | Current | |||
Engulfing Bearish | 1D | Current | |||
Completed Patterns | |||||
Engulfing Bearish | 1H | 2 | Apr 23, 2024 16:00 | ||
Engulfing Bearish | 1D | 3 | Apr 19, 2024 | ||
Abandoned Baby Bullish | 1H | 4 | Apr 23, 2024 14:00 |
Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
---|---|---|---|---|---|---|---|---|---|
NYSE | 168.21 | 0.00 | 0.00 | 324,386 | -0.78% | USD | |||
London | 168.12 | 161.38 | 176.24 | 95,839 | -0.31% | EUR | |||
BIVA | 2,880.00 | 0.00 | 0.00 | 0 | 0.00% | MXN | |||
Mexico | 2,803.98 | 2,803.98 | 3,050.00 | 0 | 0.00% | MXN | |||
Milan | 157.60 | 0.00 | 0.00 | 0 | 0.00% | EUR | |||
TradeGate | 157.00 | 157.08 | 157.56 | 508 | -0.58% | EUR | |||
Frankfurt | 159.44 | 157.04 | 157.54 | 10 | +1.63% | EUR | |||
B3 | 54.25 | 52.45 | 55.90 | 0 | 0.00% | BRL | |||
Vienna | 164.70 | 161.00 | 164.70 | 0 | +0.00% | EUR | |||
Lima | 168.80 | 0.00 | 0.00 | 18 | 0.00% | USD |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
Lloyds Banking | 52.06 | 53.22 | 49.62 | +0.72 | +1.40% | 162.56M | 14:57:33 | ||
Rolls-Royce Holdings | 419.30 | 424.20 | 416.50 | +2.10 | +0.50% | 34.72M | 14:57:33 | ||
IAG | 176.65 | 178.45 | 175.60 | +0.70 | +0.40% | 8.03M | 14:57:19 | ||
Barclays | 190.78 | 193.44 | 190.50 | -1.46 | -0.76% | 64.28M | |||
HSBC | 665.10 | 668.40 | 663.70 | -2.60 | -0.39% | 6.83M | 14:57:32 | ||
BP | 527.20 | 531.40 | 525.80 | +4.10 | +0.78% | 20.50M | 14:57:23 | ||
Vodafone Group PLC | 69.000 | 70.060 | 68.878 | -0.620 | -0.89% | 19.78M | 14:57:08 | ||
British American Tobacco | 2,346.0 | 2,378.0 | 2,343.0 | -14.0 | -0.59% | 2.06M | 14:57:25 | ||
Legal & General | 251.07 | 254.20 | 250.50 | -2.03 | -0.80% | 19.74M | |||
BAE Systems | 1,382.00 | 1,388.50 | 1,345.00 | +42.00 | +3.13% | 6.08M | 14:57:20 |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review